Development of platform for cancer epigenetic therapy by region-specific inhibition of epigenomic alteration

2017 Fiscal Year Final Research Report

• Project/Area Number: 16K15608
• Research Category: Grant-in-Aid for Challenging Exploratory Research
• Allocation Type: Multi-year Fund
• Research Field: Digestive surgery
• Research Institution: Chiba University
• Principal Investigator: Kaneda Atsushi 千葉大学, 大学院医学研究院, 教授 (10313024)
• Research Collaborator: NEMOTO Tetsuhiro 千葉大学, 大学院薬学研究院, 教授 (80361450) ; SHINOHARA Ken-ichi 千葉大学, 大学院医学研究院, 助教 (70378561) ; SUZUKI Takayoshi 京都府立医科大学, 医学系研究科, 教授 (90372838)
• Project Period (FY): 2016-04-01 – 2018-03-31
• Keywords: 癌 / エピゲノム

Outline of Final Research Achievements

Epigenomic alteration play important roles in tumorigenesis. Epigenetic inhibitors developed so far, however, reprogram the epigenome broadly and randomly; thus, unfavorable side effects can occur along with the antitumor effects, resulting in limited clinical application. To develop epigenetic inhibitors that could alter epigenetic status in region-selective manner, we here applied the technologies of DNA-binding small molecules that recognized specific DNA sequences. We conjugated epigenetic inhibotor with different small molecules, and successfully altered histone modification at different genomic regions where the specific DNA sequences recognized by the conjugated DNA-binding small molecules were frequently included.

Free Research Field

癌